Pharmacosmos predicts record financial year after launches in US and China

The intensive investments in the US and China that Pharmacosmos has made over the past few years have been expensive, but now, company leadership expects rewards.

Tobias Sidelmann Christensen, Vice President and Chief Operating Officer at Pharmacosmos (right) and his father Lars Christensen, who is CEO of the company. | Photo: Pharmacosmos / PR

Pharmacosmos has lit a fire under its dream of becoming an international company by establishing a presence in the US and China through subsidiaries and launching its main product (called Monoferric in the US and Monofer in China) on both markets.

The two new markets will contribute to growth at the Danish pharmaceutical group, which primarily earns money through Monoferric/Monofer, which is a treatment for anemia.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs